The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Effect of Myriocin on Plasma Sphingolipid Metabolism and Atherosclerosis in apoE-deficient Mice
Open accessAbstract
Sphingolipids play a very important role in cell membrane formation, signal transduction, and plasma lipoprotein metabolism, all of which may well have an impact on the development of atherosclerosis. To investigate the relationship between sphingolipid metabolism and atherosclerosis, we utilized myriocin to inhibit mouse serine palmitoyl-CoA transferase (SPT), the key enzyme for sphingolipid biosynthesis. We injected 8-week-old apoE-deficient mice with myriocin (0.3 mg/kg/every other day, intraperitoneal) for 60 days. On a chow diet, myriocin treatment caused a significant decrease (50%) in liver SPT activity (p < 0.001), significant decreases in plasma sphingomyelin, ceramide, and sphingosine-1-phosphate levels (54, 32, and 73%, respectively) (p < 0.0001), and a significant increase in plasma phosphatidylcholine levels (91%) (p < 0.0001). Plasma total cholesterol and triglyceride levels demonstrated no significant changes, but there was a significant decrease in atherosclerotic lesion area (42% in root and 36% in en face assays) (p < 0.01). On a high fat diet, myriocin treatment caused marked decreases in plasma sphingomyelin, ceramide, and sphingosine-1-phosphate levels (59, 66, and 81%, respectively) (p < 0.0001), and a marked increase in plasma phosphatidylcholine levels (100%) (p < 0.0001). Total cholesterol and triglyceride demonstrated no significant changes, but there was a significant decrease in atherosclerotic lesion area (39% in root and 37% in en face assays) (p < 0.01). These results indicate that, apart from cholesterol levels, sphingolipids have an effect on atherosclerotic development and that SPT has proatherogenic properties. Thus, inhibition of SPT activity could be an alternative treatment for atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FUJITA, T., INOUE, K., YAMAMOTO, S., IKUMOTO, T., SASAKI, S., TOYAMA, R., CHIBA, K., HOSHINO, Y., & OKUMOTO, T. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.208 · Cited by 540
Miyake, Y., Kozutsumi, Y., Nakamura, S., Fujita, T., & Kawasaki, T. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1827 · Cited by 536
Enzymes of Sphingolipid Metabolism: From Modular to Integrative Signaling
Hannun, Y. A., Luberto, C., & Argraves, K. M. (2001) · Biochemistry · doi:10.1021/bi002836k · Cited by 500
An update of the enzymology and regulation of sphingomyelin metabolism
Merrill, A. H., & Jones, D. D. (1990) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(90)90211-f · Cited by 458
Murata, N., Sato, K., Kon, J., Tomura, H., YANAGITA, M., Kuwabara, A., Ui, M., & Okajima, F. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3520809 · Cited by 407
Jiang, X.-C., Bruce, C., Mar, J., Lin, M., Ji, Y., Francone, O. L., & Tall, A. R. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5578 · Cited by 394
Self-citationPlasma Sphingomyelin Level as a Risk Factor for Coronary Artery Disease
Jiang, X.-C., Paultre, F., Pearson, T. A., Reed, R. G., Francis, C. K., Lin, M., Berglund, L., & Tall, A. R. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.12.2614 · Cited by 386
Self-citationSchissel, S. L., Tweedie-Hardman, J., Rapp, J. H., Graham, G., Williams, K. J., & Tabas, I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118934 · Cited by 341
Schissel, S. L., Schuchman, E. H., Williams, K. J., & Tabas, I. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18431 · Cited by 275
Jiang, X.-C., Qin, S., Qiao, C., Kawano, K., Lin, M., Skold, A., Xiao, X., & Tall, A. R. (2001) · Nature Medicine · doi:10.1038/89977 · Cited by 256
Self-citation
Cited by
Holland, W. L., Brozinick, J. T., Wang, L.-P., Hawkins, E. D., Sargent, K. M., Liu, Y., Narra, K., Hoehn, K. L., Knotts, T. A., Siesky, A., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.01.002 · Cited by 1,232
Ceramides in insulin resistance and lipotoxicity
SUMMERS, S. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2005.11.002 · Cited by 848
Ceramides – Lipotoxic Inducers of Metabolic Disorders
Chaurasia, B., & Summers, S. A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.07.006 · Cited by 616
A Ceramide-Centric View of Insulin Resistance
Chavez, J. A., & Summers, S. A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.002 · Cited by 610
Holland, W. L., & Summers, S. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0025 · Cited by 595
Metadata
- Authors
- Hojjati, M. R., Li, Z., Zhou, H., Tang, S., Huan, C., Ooi, E., Lu, S., & Jiang, X.-C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 280
- Issue
- 11
- Pages
- 10284-10289
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2014959138
- Cited by
- 299
- References
- 31
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Myriocin on Plasma Sphingolipid Metabolism and Atherosclerosis in apoE-deficient Mice. https://app.cochat.ai/papers/10.1074/jbc.m412348200
- The paper
- Hojjati, M. R., Li, Z., Zhou, H., Tang, S., Huan, C., Ooi, E., Lu, S., & Jiang, X.-C. (2005). Effect of Myriocin on Plasma Sphingolipid Metabolism and Atherosclerosis in apoE-deficient Mice. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m412348200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.